Nonsurgical Treatment of Nonmelanoma Skin Cancer

Dermatologic Clinics

Volumn 29, Issue 2, 2011, Pages 297-309

  Galiczynski, Edward M ^a   Vidimos, Allison T ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cryotherapy; Electrodessication and curettage; Intralesional therapies; Nonmelanoma skin cancer; PDT; Radiotherapy; Tropical therapies

Indexed keywords

ALPHA INTERFERON; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; BLEOMYCIN; CAPECITABINE; DICLOFENAC; FLUOROURACIL; HYALURONIC ACID; IMIQUIMOD; INGENOL MEBUTATE; INTERFERON; LACTIC ACID; PLACEBO; RESIQUIMOD; RESORCINOL; RETINOIC ACID; RETINOID DERIVATIVE; SALICYLIC ACID; STEROID; TAZAROTENE;

ALOPECIA; ANOREXIA; BASAL CELL CARCINOMA; BEDTIME DOSAGE; BOWEN DISEASE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOMA IN SITU; CHEILITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CONTACT DERMATITIS; CRYOSURGERY; CRYOTHERAPY; CURETTAGE; DERMATITIS; DERMATOLOGICAL PROCEDURES; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG WITHDRAWAL; ELECTRODESICCATION; ERYTHEMA; EXCISION; FACE CANCER; FATIGUE; HEAD AND NECK TUMOR; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; LASER SURGERY; MELANOMA; MYALGIA; NAUSEA; PAIN; PHOTODYNAMIC THERAPY; POROKERATOSIS; PRIORITY JOURNAL; PRURITUS; RAYNAUD PHENOMENON; REVIEW; SKIN BURNING SENSATION; SKIN CANCER; SKIN EDEMA; SKIN INFLAMMATION; SKIN IRRITATION; SKIN PAIN; SKIN SURGERY; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TISSUE NECROSIS; TREATMENT INDICATION; VERRUCA VULGARIS;

ANTINEOPLASTIC AGENTS; CRYOTHERAPY; HUMANS; INCIDENCE; RISK FACTORS; SKIN NEOPLASMS;

EID: 79952748672     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2011.01.011     Document Type: Review

References (90)

1. Werlinger KD, Upton G., Moore AY Recurrence rates of primary nonmelanoma skin cancers treated by surgical excision compared to electrodessication-curettage in a private dermatological practice. Dermatol Surg 2002, 28(12):1138-1142. [discussion: 1142].
2. Silverman M.K., Kopf A.W., Gladstein A.H., et al. Recurrence rates of treated basal cell carcinomas. Part 4: x-ray therapy. J Dermatol Surg Oncol 1992, 18(7):549-554.
3. Sheridan A.T., Dawber R.P. Curettage, electrosurgery and skin cancer. Australas J Dermatol 2000, 41(1):19-30.
4. Ahmed I., Berth-Jones J., Charles-Holmes S., et al. Comparison of cryotherapy with curettage in the treatment of Bowen's disease: a prospective study. Br J Dermatol 2000, 143(4):759-766.
5. Wang I., Bendsoe N., Klinteberg C.A., et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001, 144(4):832-840.
6. Bath-Hextall F.J., Perkins W., Bong J., et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007, 1. CD003412.
7. Hall V.L., Leppard B.J., Mcgill J., et al. Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol 1986, 37(1):33-34.
8. Thissen M.R., Nieman F.H., Ideler A.H., et al. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg 2000, 26(8):759-764.
9. Braathen L.R., Szeimies R.M., Basset-Seguin N., et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol 2007, 56(1):125-143.
10. Morton C., Horn M., Leman J., et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol 2006, 142(6):729-735.
11. Hadley G., Derry S., Moore R.A. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 2006, 126(6):1251-1255.
12. Swanson N., Abramovits W., Berman B., et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol 2010, 62(4):582-590.
13. Marks R., Gebauer K., Shumack S., et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001, 44(5):807-813.
14. Geisse J.K., Rich P., Pandya A., et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002, 47(3):390-398.
15. Quirk C., Gebauer K., De'Ambrosis B., et al. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis 2010, 85(6):318-324.
16. Huber A., Huber J.D., Skinner R.B., et al. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. Dermatol Surg 2004, 30(3):429-430.
17. Shumack S., Robinson J., Kossard S., et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002, 138(9):1165-1171.
18. Mackenzie-Wood A., Kossard S., De Launey J., et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001, 44(3):462-470.
19. Martin-Garcia R.F. Imiquimod: an effective alternative for the treatment of invasive cutaneous squamous cell carcinoma. Dermatol Surg 2005, 31(3):371-374.
20. Longley D.B., Harkin D.P., Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3(5):330-338.
21. Falkson G., Schulz E.J. Skin changes in patients treated with 5-fluorouracil. Br J Dermatol 1962, 74:229-236.
22. Dillaha C.J., Jansen G.T., Honeycutt W.M., et al. Selective cytotoxic effect of topical 5-fluorouracil. Arch Dermatol 1963, 88:247-256.
23. Drake L.A., Ceilley R.I., Cornelison R.L., et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol 1995, 32(1):95-98.
24. Bargman H., Hochman J. Topical treatment of Bowen's disease with 5-fluorouracil. J Cutan Med Surg 2003, 7(2):101-105.
25. Loven K., Stein L., Furst K., et al. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002, 24(6):990-1000.
26. Johnson M.R., Hageboutros A., Wang K., et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999, 5(8):2006-2011.
27. Goette D.K., Odom R.B., Arrott J.W., et al. Treatment of keratoacanthoma with topical application of fluorouracil. Arch Dermatol 1982, 118(5):309-311.
28. Peters D.C., Foster R.H. Diclofenac/hyaluronic acid. Drugs Aging 1999, 14(4):313-319. [discussion: 320-1].
29. Marks F., Furstenberger G., Muller-Decker K. Metabolic targets of cancer chemoprevention: interruption of tumor development by inhibitors of arachidonic acid metabolism. Recent Results Cancer Res 1999, 151:45-67.
30. Masferrer J.L., Leahy K.M., Koki A.T., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000, 60(5):1306-1311.
31. Berman B., Villa A.M., Ramirez C.C. Mechanisms of action of new treatment modalities for actinic keratosis. J Drugs Dermatol 2006, 5(2):167-173.
32. Tutrone W.D., Saini R., Caglar S., et al. Topical therapy for actinic keratoses, II: diclofenac, colchicine, and retinoids. Cutis 2003, 71(5):373-379.
33. Peris K., Fargnoli M.C., Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N Engl J Med 1999, 341(23):1767-1768.
34. Weinstein G.D., Koo J.Y., Krueger G.G., et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003, 48(5):760-767.
35. Marks R. Pharmacokinetics and safety review of tazarotene. J Am Acad Dermatol 1998, 39(4 Pt 2):S134-S138.
36. Weinstein G.D., Krueger G.G., Lowe N.J., et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997, 37(1):85-92.
37. De Graaf Y.G., Euvrard S., Bouwes Bavinck J.N. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg 2004, 30(4 Pt 2):656-661.
38. Chakrabarty A., Geisse J.K. Medical therapies for non-melanoma skin cancer. Clin Dermatol 2004, 22(3):183-188.
39. Ogbourne S.M., Suhrbier A., Jones B., et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res 2004, 64(8):2833-2839.
40. Challacombe J.M., Suhrbier A., Parsons P.G., et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 2006, 177(11):8123-8132.
41. Siller G., Gebauer K., Welburn P., et al. Pep005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol 2009, 50(1):16-22.
42. Anderson L., Schmieder G.J., Werschler W.P., et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol 2009, 60(6):934-943.
43. Tomai M.A., Gibson S.J., Imbertson L.M., et al. Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res 1995, 28(3):253-264.
44. Testerman T.L., Gerster J.F., Imbertson L.M., et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995, 58(3):365-372.
45. Jones T. Resiquimod 3M. Curr Opin Investig Drugs 2003, 4(2):214-218.
46. Szeimies R.M., Bichel J., Ortonne J.P., et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol 2008, 159(1):205-210.
47. Lawrence N., Cox S.E., Cockerell C.J., et al. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 1995, 131(2):176-181.
48. Jiang S.B., Levine V.J., Nehal K.S., et al. Er:YAG laser for the treatment of actinic keratoses. Dermatol Surg 2000, 26(5):437-440.
49. Iyer S., Friedli A., Bowes L., et al. Full face laser resurfacing: therapy and prophylaxis for actinic keratoses and non-melanoma skin cancer. Lasers Surg Med 2004, 34(2):114-119.
50. Humphreys T.R., Malhotra R., Scharf M.J., et al. Treatment of superficial basal cell carcinoma and squamous cell carcinoma in situ with a high-energy pulsed carbon dioxide laser. Arch Dermatol 1998, 134(10):1247-1252.
51. Hantash B.M., Stewart D.B., Cooper Z.A., et al. Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol 2006, 142(8):976-982.
52. Iyer S., Bowes L., Kricorian G., et al. Treatment of basal cell carcinoma with the pulsed carbon dioxide laser: a retrospective analysis. Dermatol Surg 2004, 30(9):1214-1218.
53. Morse L.G., Kendrick C., Hooper D., et al. Treatment of squamous cell carcinoma with intralesional 5-fluorouracil. Dermatol Surg 2003, 29(11):1150-1153. [discussion: 1153].
54. Miller B.H., Shavin J.S., Cognetta A., et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. J Am Acad Dermatol 1997, 36(1):72-77.
55. James M.P., Collier P.M., Aherne W., et al. Histologic, pharmacologic, and immunocytochemical effects of injection of bleomycin into viral warts. J Am Acad Dermatol 1993, 28(6):933-937.
56. Munkvad M., Genner J., Staberg B., et al. Locally injected bleomycin in the treatment of warts. Dermatologica 1983, 167(2):86-89.
57. Gyurova M.S., Stancheva M.Z., Arnaudova M.N., et al. Intralesional bleomycin as alternative therapy in the treatment of multiple basal cell carcinomas. Dermatol Online J 2006, 12(3):25.
58. Amer M., Diab N., Ramadan A., et al. Therapeutic evaluation for intralesional injection of bleomycin sulfate in 143 resistant warts. J Am Acad Dermatol 1988, 18(6):1313-1316.
59. Shumer S.M., O'keefe E.J. Bleomycin in the treatment of recalcitrant warts. J Am Acad Dermatol 1983, 9(1):91-96.
60. Buechner S.A., Wernli M., Harr T., et al. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by Cd95 (Apo-1/Fas)-Cd95 ligand-induced suicide. J Clin Invest 1997, 100(11):2691-2696.
61. Kim K.H., Yavel R.M., Gross V.L., et al. Intralesional interferon alpha-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited. Dermatol Surg 2004, 30(1):116-120.
62. Angell-Petersen E., Sorensen R., Warloe T., et al. Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Invest Dermatol 2006, 126(2):265-271.
63. Touma D., Yaar M., Whitehead S., et al. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol 2004, 140(1):33-40.
64. Piacquadio D.J., Chen D.M., Farber H.F., et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol 2004, 140(1):41-46.
65. Garcia-Zuazaga J., Cooper K.D., Baron Ed Photodynamic therapy in dermatology: current concepts in the treatment of skin cancer. Expert Rev Anticancer Ther 2005, 5(5):791-800.
66. Blume J.E., Oseroff A.R. Aminolevulinic acid photodynamic therapy for skin cancers. Dermatol Clin 2007, 25(1):5-14.
67. Kalisiak M.S., Rao J. Photodynamic therapy for actinic keratoses. Dermatol Clin 2007, 25(1):15-23.
68. Morton C., Campbell S., Gupta G., et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol 2006, 155(5):1029-1036.
69. Smith S., Piacquadio D., Morhenn V., et al. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol 2003, 2(6):629-635.
70. Kurwa H.A., Yong-Gee S.A., Seed P.T., et al. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 1999, 41(3 Pt 1):414-418.
71. Freeman M., Vinciullo C., Francis D., et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003, 14(2):99-106.
72. Tarstedt M., Rosdahl I., Berne B., et al. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol 2005, 85(5):424-428.
73. Pariser D.M., Lowe N.J., Stewart D.M., et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003, 48(2):227-232.
74. Tschen E.H., Wong D.S., Pariser D.M., et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase iv multicentre clinical trial with 12-month follow up. Br J Dermatol 2006, 155(6):1262-1269.
75. Morton C.A., Whitehurst C., Moseley H., et al. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol 1996, 135(5):766-771.
76. Thestrup-Pedersen K., Ravnborg L., Reymann F. Morbus Bowen. A description of the disease in 617 patients. Acta Derm Venereol 1988, 68(3):236-239.
77. Ball S.B., Dawber R.P. Treatment of cutaneous Bowen's disease with particular emphasis on the problem of lower leg lesions. Australas J Dermatol 1998, 39(2):63-68. [quiz: 69-70].
78. Morton C.A. Methyl aminolevulinate: actinic keratoses and Bowen's disease. Dermatol Clin 2007, 25(1):81-87.
79. Morton C.A., Whitehurst C., Mccoll J.H., et al. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 2001, 137(3):319-324.
80. Wollina U., Hansel G., Koch A., et al. Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. J Cancer Res Clin Oncol 2005, 131:300-304.
81. Cartei G., Cartei F., Interlandi G., et al. Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 2000, 23:181-184.
82. Clark C., Bryden A., Dawe R., et al. Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. Photodermatol Photoimmunol Photomed 2003, 19(3):134-141.
83. Kennedy J.C., Pottier R.H., Pross D.C. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990, 6(1-2):143-148.
84. Basset-Seguin N., Ibbotson S.H., Emtestam L., et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008, 18(5):547-553.
85. Caekelbergh K., Nikkels A.F., Leroy B., et al. Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes. J Drugs Dermatol 2009, 8(11):992-996.
86. Soler A.M., Warloe T., Berner A., et al. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol 2001, 145(3):467-471.
87. Tope W.D., Menter A., El-Azhary R.A., et al. Comparison of topical methyl aminolevulinate photodynamic therapy versus placebo photodynamic therapy in nodular BCC. J Eur Acad Dermatol Venereol 2004, 18(Suppl 2):413-414.
88. Foley P., Freeman M., Menter A., et al. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol 2009, 48(11):1236-1245.
89. Salim A., Leman J.A., McColl J.H., et al. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol 2003, 148(3):539-543.
90. Calzavara-Pinton P.G., Venturini M., Sala R., et al. Methylaminolaevulinate-based photodynamic therapy of Bowen's disease and squamous cell carcinoma. Br J Dermatol 2008, 159(1):137-144.